

MARKET REPORT



EpiCast Report: Heart Failure - Epidemiology Forecast to 2025

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



EpiCast Report: Heart Failure - Epidemiology Forecast to 2025

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

EpiCast Report: Heart Failure - Epidemiology Forecast to 2025

EpiCast Report: Heart Failure - Epidemiology Forecast to 2025

Summary

Heart Failure (HF), also referred to as congestive cardiac failure, is a heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic needs of the body. Eventually, without the heart's pumping action to deliver oxygen and nutrient-rich blood to the cells, fatigue, shortness of breath, and coughing results. HF commonly occurs in people above 50 years of age, and severity increases progressively with age. Symptoms can develop quickly, such as in acute HF, at which time the patient needs to be hospitalized. However, in chronic HF, the symptoms develop gradually. Due to the chronic nature of cardiovascular diseases, many of the risk factors for HF, such as chronic obstructive pulmonary disease (COPD) and anemia, are also comorbid conditions.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed incident cases of HF will increase from 1,094,344 cases in 2015 to 1,400,377 cases in 2025 at an Annual Growth Rate (AGR) of 2.80%. In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of chronic HF will increase from 13,756,453 cases in 2015 to 16,105,489 cases in 2025 at an AGR of 1.71%. The US will have the highest number of diagnosed incident cases of HF and diagnosed prevalent cases of chronic HF among the 7MM throughout the forecast period with 1,052,831 diagnosed incident cases of HF and 6,170,142 diagnosed prevalent cases of chronic HF in 2025. In the 7MM in 2015, 37.59% of the diagnosed prevalent cases of chronic HF are in NYHA Class I, 39.54% in NYHA Class II, 19.11% in NYHA Class III, and 3.75% in NYHA Class IV.

GlobalData epidemiologists utilized comprehensive, country-specific data from national HF registers and peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the diagnosed incident cases of HF, as well as the diagnosed prevalent cases of chronic HF. In this analysis, GlobalData epidemiologists provide detailed, clinically relevant segmentations for diagnosed incident and diagnosed prevalent cases of HF. Finally, the same forecast methodology was used across the 7MM, thereby allowing for meaningful global comparisons of the diagnosed incident and diagnosed prevalent cases of HF across these markets.

Scope

- The Heart Failure (HF) EpiCast Report provides an overview of the risk factors and global trends of HF in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of HF diagnosed incident and diagnosed prevalent cases segmented by age and sex. Diagnosed incident cases are further segmented by ejection fraction, ventricular dysfunction, acute HF hospitalizations (by worsening HF, advanced HF, de novo HF), re-admissions (within 3 months) post-discharge after acute HF hospitalization, and hospital length of stay for acute HF hospitalization in these seven markets. Diagnosed prevalent cases are further segmented by chronic HF (by ejection fraction), and also classified according to the New York Heart Association (NYHA) functional classes I-IV, and American College of Cardiology Foundation/American Heart Association (ACCF/AHA) stages B, C and D in these seven markets.

- The HF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The HF EpiCast report will allow you to -

- Develop business strategies by understanding the trends shaping and driving the global HF market.
- Quantify patient populations in the global HF market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HF therapeutics in each of the markets covered.
- Identify the percentage of HF diagnosed incident and diagnosed prevalent cases by various clinical segmentations.

Additional Details

Publisher : Global Data

Reference : GDHCER117-16

Number of Pages : 77

Report Format : PDF

Publisher Information :



GlobalData »

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for EpiCast Report: Heart Failure - Epidemiology Forecast to 2025

- 1 Table of Contents1 Table of Contents 51.1 List of Tables 61.2 List of Figures 72 Epidemiology 92.1 Disease Background 92.2 Risk Factors and Comorbidities 102.3 Global Trends 122.3.1 US 122.3.2 5EU 132.3.3 Japan 142.4 Forecast Methodology. 152.4.1 Sources Used Tables 172.4.2 Forecast Assumptions and Methods 202.4.3 Sources Not Used 352.5 Epidemiological Forecast for HF (2015-2025) 362.5.1 Diagnosed Incident Cases 362.5.2 Diagnosed Prevalent Cases 492.6 Discussion 612.6.1 Epidemiological Forecast Insight 612.6.2 Limitations of the Analysis 612.6.3 Strengths of the Analysis 623 Appendix 633.1 Bibliography 633.2 About the Authors 723.2.1 Epidemiologists 723.2.2 Reviewers 723.2.3 Global Director of Therapy Analysis and Epidemiology 733.2.4 Global Head of Healthcare 743.3 About GlobalData 753.4 About EpiCast 753.5 Disclaimer 76

List Of Tables in EpiCast Report: Heart Failure - Epidemiology Forecast to 2025

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for HF 11

Table 2: NYHA Functional Classes I-IV 16

Table 3: ACCF/AHA Stages A, B, C, and D 17

Table 4: 7MM, Sources of Epidemiological Data Used for the Forecast of HF Diagnosed Incident Cases 17

Table 5: 7MM, Sources of Epidemiological Data Used for the Forecast of Chronic HF Diagnosed Prevalent Cases 18

Table 6: 7MM, Sources of Epidemiological Data Used for the Classification of Diagnosed Prevalent Cases of Chronic HF According to the NYHA Functional Classes I-IV 19

Table 7: 7MM, Sources of Epidemiological Data Used for Forecast of HF Diagnosed Incident Cases of Acute HF Hospitalizations 20

Table 8: 7MM, Sources Not Used in Epidemiological Analysis of HF 35

Table 9: 7MM, Diagnosed Incident Cases of HF, Ages ≥ 45 Years, Both Sexes, N, 2015-2025 37

Table 10: 7MM, Age-Specific Diagnosed Incident Cases of HF, Both Sexes, N (Row %), 2015 38

Table 11: 7MM, Sex-Specific Diagnosed Incident Cases of HF, Ages ≥ 45 Years, N (Row %), 2015 40

Table 12: 7MM, Diagnosed Incident Cases of Acute HF Hospitalizations, Ages ≥ 45 Years, Both Sexes, N, 2015-2025 45

Table 13: 7MM, Readmissions (Within Three Months) Post-Discharge After Acute HF Hospitalization Among Diagnosed Incident Cases of Acute HF, Ages ≥ 45 Years, Both Sexes, N, 2015-2025 47

Table 14: 7MM, Diagnosed Prevalent Cases of Chronic HF, Ages ≥ 45 Years, Both Sexes, N, 2015-2025 50

Table 15: 7MM, Age-Specific Diagnosed Prevalent Cases of Chronic HF, Both Sexes, N (Row %), 2015 52

Table 16: 7MM, Sex-Specific Diagnosed Prevalent Cases of Chronic HF, Ages ≥ 45 Years, N (Row %), 2015 54

List Of Figures, Charts and Diagrams in EpiCast Report: Heart Failure - Epidemiology Forecast to 2025

1.2 List of Figures

Figure 1: 7MM, Diagnosed Incident Cases of HF, Ages ≥ 45 Years, Both Sexes, N, 2015-2025 37

Figure 2: 7MM, Diagnosed Incident Cases of HF by Age Group, Both Sexes, N, 2015 39

Figure 3: 7MM, Sex-Specific Diagnosed Incident Cases of HF, Ages ≥ 45 Years, N, 2015 41

Figure 4: 7MM, Age-Standardized Diagnosed Incidence of HF (Cases per 100,000 Population), Ages ≥ 45 Years, by Sex, 2015 42

Figure 5: 7MM, Diagnosed Incident Cases of HF Segmented by EF, Ages ≥ 45 Years, Both Sexes, N, 2015 43

Figure 6: 7MM, Diagnosed Incident Cases of HF Segmented by Ventricular Dysfunction, Ages ≥ 45 Years, Both Sexes, N, 2015 44

Figure 7: 7MM, Diagnosed Incident Cases of Acute HF Hospitalizations, Ages ≥ 45 Years, Both Sexes, N, 2015-2025 45

Figure 8: 7MM, Diagnosed Incident Cases of Acute HF Hospitalizations, Ages ≥ 45 Years, Both Sexes, N, 2015 46

Figure 9: 7MM, Readmissions (Within Three Months) Post-Discharge After Acute HF Hospitalization Among Diagnosed Incident Cases of Acute HF, Ages ≥ 45 Years, Both Sexes, N, 2015-2025 48

Figure 10: 7MM, Hospital Length Of Stay For Acute HF Hospitalization, Ages ≥ 45 Years, Both Sexes, Days, 2015 49

Figure 11: 7MM, Diagnosed Prevalent Cases of Chronic HF, Ages ≥ 45 Years, Both Sexes, N, 2015-2025 51

Figure 12: 7MM, Age-Specific Diagnosed Prevalent Cases of Chronic HF, Both Sexes, N, 2015 53

Figure 13: 7MM, Sex-Specific Diagnosed Prevalent Cases of Chronic HF, Ages ≥ 45 Years, N, 2015 55

Figure 14: 7MM, Age-Standardized Diagnosed Prevalence of Chronic HF (%), Ages ≥ 45 Years, by Sex, 2015 56

Figure 15: 7MM, Diagnosed Prevalent Cases of Chronic HF Segmented by EF, Ages ≥ 45 Years, Both Sexes, N, 2015 57

Figure 16: 7MM, Diagnosed Prevalent Cases of Chronic HF Segmented by NYHA Classes, Ages ≥ 45 Years, Both Sexes, N, 2015 58

Figure 17: 7MM, Diagnosed Prevalent Cases of Chronic HF Segmented by ACCF/AHA Stages, Ages ≥ 45 Years, Both Sexes, N, 2015 59

Figure 18: 7MM, Prevalent Cases of Comorbidities Among Diagnosed Prevalent Cases of Chronic HF, Both Sexes, Ages ≥ 45 Years, N, 2015 60

How to Buy...

EpiCast Report: Heart Failure - Epidemiology Forecast to 2025

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/26671>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$3995** | Single User Price
- \$7990** | Site License Price
- \$11985** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.